Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 2 of 116

  1. 5-Fluorouracil

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. 5-Fluoruracil

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  3. 5-Fu/epirubicin/CTX following Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 3 small molecule active

    1 trial

  4. 56021927PCR3001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  5. 56021927PCR3002

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. 56021927PCR3015

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  7. 6-Thio-2'-Deoxyguanosine

    MAIA Biotechnology

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    2 trials

  8. 6-month course of antiandrogen drugs

    The First People's Hospital of Lianyungang

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  9. 61186372COR3001

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  10. 61186372COR3002

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  11. 61186372HNC3001

    Janssen-Cilag International N.V.

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  12. 61186372NSC3001

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. 61186372NSC3002

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. 61186372NSC3004

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. 64091742PCR3001

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  16. 64Cu(II)Cl2 solution for injection

    A.C.O.M. - Advanced Center Oncology

    Cancer on the prostatic bed

    phase 3 small molecule active

    1 trial

  17. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  18. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  19. 67652000PCR3002

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  20. 68Ga-PSMA-11

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biochemical Recurrence of Malignant Neoplasm of Prostate

    phase 3 small molecule active

    1 trial

  21. 73841937NSC3003

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. 7465-CL-0301

    Astellas Pharma GmbH

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  23. 78278343PCR3001

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  24. 78278343PCR3003

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  25. 8951-CL-0301

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  26. 8951-CL-0302

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  27. 8951-CL-0305

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  28. 89Zr-CED88004S

    Disc Medicine

    Large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  29. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Cell Carcinoma

    phase 3 small molecule completed

    2 trials

  30. 89Zr-TLX250 PET/CT

    Telix Innovations

    Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  31. 91782

    Bayer HealthCare AG

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  32. A021502

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  33. ABC-HCC

    The George Institute

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  34. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  35. ABP 206

    Amgen

    Melanoma

    phase 3 small molecule active

    2 trials

  36. ABX-CT-302EU/EAGLE-i

    Advanced Accelerator Applications

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  37. AC220-168

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  38. ACE-536-MF-002

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  39. ACE-CL-007

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  40. ACE-CL-311 (AMPLIFY)

    Lacuna Pharma Pty Ltd

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  41. ACE-LY-308

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  42. ADAURA - D5164C00001

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  43. ADSTILADRIN

    Ferring Pharmaceuticals

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  44. AFMMUChina

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  45. AG120-C-009

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial

  46. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  47. ALKS 4230-007

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  48. ALL2820

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.